541 related articles for article (PubMed ID: 31054010)
1. A randomised, double-blind, placebo-controlled trial of a multi-strain probiotic in patients with asymptomatic ulcerative colitis and Crohn's disease.
Bjarnason I; Sission G; Hayee B
Inflammopharmacology; 2019 Jun; 27(3):465-473. PubMed ID: 31054010
[TBL] [Abstract][Full Text] [Related]
2. Randomised clinical trial: A liquid multi-strain probiotic vs. placebo in the irritable bowel syndrome--a 12 week double-blind study.
Sisson G; Ayis S; Sherwood RA; Bjarnason I
Aliment Pharmacol Ther; 2014 Jul; 40(1):51-62. PubMed ID: 24815298
[TBL] [Abstract][Full Text] [Related]
3. Conventional therapy for moderate to severe inflammatory bowel disease: A systematic literature review.
Damião AOMC; de Azevedo MFC; Carlos AS; Wada MY; Silva TVM; Feitosa FC
World J Gastroenterol; 2019 Mar; 25(9):1142-1157. PubMed ID: 30863001
[TBL] [Abstract][Full Text] [Related]
4. Neopterin is a novel reliable fecal marker as accurate as calprotectin for predicting endoscopic disease activity in patients with inflammatory bowel diseases.
Nancey S; Boschetti G; Moussata D; Cotte E; Peyras J; Cuerq C; Haybrard J; Charlois AL; Mialon A; Chauvenet M; Stroeymeyt K; Kaiserlian D; Drai J; Flourié B
Inflamm Bowel Dis; 2013 Apr; 19(5):1043-52. PubMed ID: 23511035
[TBL] [Abstract][Full Text] [Related]
5. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis.
Miele E; Pascarella F; Giannetti E; Quaglietta L; Baldassano RN; Staiano A
Am J Gastroenterol; 2009 Feb; 104(2):437-43. PubMed ID: 19174792
[TBL] [Abstract][Full Text] [Related]
6. Probiotics in the Treatment of Inflammatory Bowel Disease in Adulthood: A Systematic Review.
Lorentz A; Müller L
J Gastrointestin Liver Dis; 2022 Mar; 31(1):74-84. PubMed ID: 35306546
[TBL] [Abstract][Full Text] [Related]
7. GlycA, a Nuclear Magnetic Resonance Spectroscopy Measure for Protein Glycosylation, is a Viable Biomarker for Disease Activity in IBD.
Dierckx T; Verstockt B; Vermeire S; van Weyenbergh J
J Crohns Colitis; 2019 Mar; 13(3):389-394. PubMed ID: 30312386
[TBL] [Abstract][Full Text] [Related]
8. The INHABIT (synergIstic effect of aNtHocyAnin and proBIoTics in) Inflammatory Bowel Disease trial: a study protocol for a double-blind, randomised, controlled, multi-arm trial.
Cosier D; Lambert K; Batterham M; Sanderson-Smith M; Mansfield KJ; Charlton K
J Nutr Sci; 2024; 13():e1. PubMed ID: 38282655
[TBL] [Abstract][Full Text] [Related]
9. Probiotic and prebiotic use in patients with inflammatory bowel disease: a case-control study.
Hedin CR; Mullard M; Sharratt E; Jansen C; Sanderson JD; Shirlaw P; Howe LC; Djemal S; Stagg AJ; Lindsay JO; Whelan K
Inflamm Bowel Dis; 2010 Dec; 16(12):2099-108. PubMed ID: 20848469
[TBL] [Abstract][Full Text] [Related]
10. Probiotics in the management of inflammatory bowel disease: a systematic review of intervention studies in adult patients.
Jonkers D; Penders J; Masclee A; Pierik M
Drugs; 2012 Apr; 72(6):803-23. PubMed ID: 22512365
[TBL] [Abstract][Full Text] [Related]
11. Rationale for probiotic and antibiotic treatment strategies in inflammatory bowel diseases.
Schultz M; Schölmerich J; Rath HC
Dig Dis; 2003; 21(2):105-28. PubMed ID: 14571109
[TBL] [Abstract][Full Text] [Related]
12. Crohn's disease and ulcerative colitis. Occurrence, course and prognosis during the first year of disease in a European population-based inception cohort.
Burisch J
Dan Med J; 2014 Jan; 61(1):B4778. PubMed ID: 24393595
[TBL] [Abstract][Full Text] [Related]
13. Probiotics for inflammatory bowel diseases: a promising adjuvant treatment.
Coqueiro AY; Raizel R; Bonvini A; Tirapegui J; Rogero MM
Int J Food Sci Nutr; 2019 Feb; 70(1):20-29. PubMed ID: 29804478
[TBL] [Abstract][Full Text] [Related]
14. Does probiotic supplementation improve quality of life in mild-to-moderately active ulcerative colitis patients in Jordan? A secondary outcome of the randomized, double-blind, placebo-controlled study.
Rayyan YM; Agraib LM; Alkhatib B; Yamani MI; Abu-Sneineh AT; Tayyem RF
Eur J Nutr; 2023 Oct; 62(7):3069-3077. PubMed ID: 37498369
[TBL] [Abstract][Full Text] [Related]
15. New insights into the biological and clinical significance of fecal calprotectin in inflammatory bowel disease.
Amati L; Passeri ME; Selicato F; Mastronardi ML; Penna A; Jirillo E; Covelli V
Immunopharmacol Immunotoxicol; 2006; 28(4):665-81. PubMed ID: 17190742
[TBL] [Abstract][Full Text] [Related]
16. Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy.
Colombel JF; Jharap B; Sandborn WJ; Feagan B; Peyrin-Biroulet L; Eichner SF; Robinson AM; Mostafa NM; Zhou Q; Thakkar RB
Aliment Pharmacol Ther; 2017 Jan; 45(1):50-62. PubMed ID: 27883215
[TBL] [Abstract][Full Text] [Related]
17. Fecal HMGB1 Reveals Microscopic Inflammation in Adult and Pediatric Patients with Inflammatory Bowel Disease in Clinical and Endoscopic Remission.
Palone F; Vitali R; Cucchiara S; Mennini M; Armuzzi A; Pugliese D; DʼIncà R; Barberio B; Stronati L
Inflamm Bowel Dis; 2016 Dec; 22(12):2886-2893. PubMed ID: 27755215
[TBL] [Abstract][Full Text] [Related]
18. Antibiotics and probiotics in treatment of inflammatory bowel disease.
Gionchetti P; Rizzello F; Lammers KM; Morselli C; Sollazzi L; Davies S; Tambasco R; Calabrese C; Campieri M
World J Gastroenterol; 2006 Jun; 12(21):3306-13. PubMed ID: 16733845
[TBL] [Abstract][Full Text] [Related]
19. Bi-directionality of Brain-Gut Interactions in Patients With Inflammatory Bowel Disease.
Gracie DJ; Guthrie EA; Hamlin PJ; Ford AC
Gastroenterology; 2018 May; 154(6):1635-1646.e3. PubMed ID: 29366841
[TBL] [Abstract][Full Text] [Related]
20. Eicosapentaenoic Acid Reduces Fecal Levels of Calprotectin and Prevents Relapse in Patients With Ulcerative Colitis.
Scaioli E; Sartini A; Bellanova M; Campieri M; Festi D; Bazzoli F; Belluzzi A
Clin Gastroenterol Hepatol; 2018 Aug; 16(8):1268-1275.e2. PubMed ID: 29391271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
